Moderna Gets $50M to Fast-Track Ebola Vaccine for DRC

Scientists are racing to develop the first-ever vaccine against a rare Ebola strain that's spreading rapidly through the Democratic Republic of Congo, and they're using the same proven technology that brought us COVID-19 vaccines.

The Coalition for Epidemic Preparedness Innovations announced Monday it's investing over $60 million to develop three vaccine candidates against Bundibugyo ebolavirus. This particular strain has caused only two previous outbreaks, which means no approved vaccines or treatments exist for it yet.

Moderna is receiving $50 million to develop an mRNA-based vaccine using the same platform that allowed rapid COVID-19 vaccine development. The funding will support early testing and prepare manufacturing for large-scale trials if the vaccine succeeds.

"We believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," said Moderna CEO Stéphane Bancel. The company promises to move with both urgency and scientific rigor to help communities most in need.

Two other organizations are also joining the fight. The International AIDS Vaccine Initiative received $3.2 million to develop a vaccine using technology similar to the approved Zaire Ebola vaccine. The University of Oxford and Serum Institute of India got $8.6 million to adapt their adenovirus vaccine platform, which they successfully used for COVID-19.

The current outbreak has health officials concerned. As of Friday, the World Health Organization reported 1,041 cases and 241 deaths, though most remain unconfirmed due to challenging conditions on the ground.

The outbreak faces multiple obstacles beyond the lack of vaccines. Delayed detection allowed the virus to spread before officials could respond. The affected region struggles with armed conflict, large population movements, and significant humanitarian needs.

The Ripple Effect

This emergency funding shows how pandemic preparedness investments are already paying off. The mRNA and adenovirus platforms developed during COVID-19 can now be quickly adapted for other deadly diseases, potentially saving months or years in vaccine development.

The existing Ebola vaccines for other strains have already proven this approach works. Both currently licensed vaccines target the more common Zaire strain, which has caused most large outbreaks historically.

Now communities facing the Bundibugyo strain have genuine hope for protection where none existed before.